|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:buprenorphine
|
|
gptkbp:agonistOf
|
delta-opioid receptor (antagonist)
kappa-opioid receptor (antagonist)
mu-opioid receptor (partial)
|
|
gptkbp:approvalYear
|
2002 (US)
|
|
gptkbp:associatedWith
|
gptkb:Suboxone
Bunavail
Zubsolv
|
|
gptkbp:ATCCode
|
N07BC01
|
|
gptkbp:brand
|
gptkb:buprenorphine
|
|
gptkbp:chemicalClass
|
opioid
|
|
gptkbp:contraindication
|
severe respiratory depression
acute alcoholism
hypersensitivity to buprenorphine
|
|
gptkbp:controlledSubstanceSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:drugInteraction
|
gptkb:beer
gptkb:benzodiazepines
other CNS depressants
|
|
gptkbp:eliminationHalfLife
|
24-60 hours
|
|
gptkbp:enemyOf
|
gptkb:mu-opioid_receptor
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:genericName
|
yes
|
|
gptkbp:halfLife
|
24-60 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Subutex
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
Indivior
|
|
gptkbp:marketedAs
|
gptkb:France
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:Europe
gptkb:France
gptkb:India
gptkb:New_Zealand
gptkb:Russia
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseTreatment
|
gptkb:naloxone
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
sublingual
buccal
|
|
gptkbp:sideEffect
|
nausea
constipation
headache
sweating
insomnia
|
|
gptkbp:usedFor
|
pain management
opioid dependence
|
|
gptkbp:bfsParent
|
gptkb:Buprenorphine
gptkb:buprenorphine
|
|
gptkbp:bfsLayer
|
6
|